Congress Abstracts

2016 – SITC Abstract – NBTXR3 for in situ cancer vaccination

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

NBTXR3 exposed to irradiation enhanced cancer cells destruction and immunogenic cell death compared to irradiation alone, suggesting a strong potential for transforming tumor into an effective in situ vaccine. This may contribute to transform “cold” tumor into “hot” tumor and effectively be combined with most of the immunotherapeutic agents across oncology. NBTXR3 is intended to be injected in the tumors. Spilling in the circulation may occur during product administration or, as expected, during tumor destruction, leading to steady trapping of NPs in the reticulo-endothelial system (liver and spleen). Clinically, it is unknown whether patients, previously treated with NPs, may show toxic signs when NPs are exposed (activation) to diagnosis imaging (computed tomography(CT)) of the liver.

2015 – Clinical Sciences and Drug Discovery Abstract – Use of metals as nano-sized radiation enhancers – Pottier et al.

Congress Abstracts, Miscellaneous

Since the discovery of cisplatin about 40 years ago, the design of innovative metal-based anticancer drugs is a growing area of research. Metal elements offer specific characteristics due to their intrinsic properties and could be used in relation to their final state: a metal complex, a radionuclide, a metal-based nanoparticle product. Transition metal coordination complexes interact with cell molecular targets, affecting biochemical functions resulting in cancer cell destruction. Radionuclides are another way to use metals as anticancer therapy. The metal nucleus of the unstable radionuclide becomes stable by emitting energy. The biological effect in different tissues is obtained by the absorption of this energy from the radiation emitted by the radionuclide, the principal target generally agreed for ionizing radiations being DNA. A new area of clinical research is now emerging using the same experimental metal elements, but in a radically different manner: metals and metal oxides used as crystalline nanosized radiation enhancers particles. The use of metals as a high electron density material tailored at the nanoscale when exposed to radiotherapy is a unique approach that can allow entry to the cell and make feasible the absorption/deposition of a high-energy dose within the tumor cell (on/off activity). Therefore, high electron density metal or metal oxide nanoparticles may bring well known physical mode of action, that of radiotherapy, within malignant cells and achieve the paradigm of local cancer treatment.

2014 – ASCO Abstract – Preliminary Data NBTXR3 Soft Tissue Sarcoma – Bonvalot et al.

Clinical Data NBTXR3, Congress Abstracts, STS

Functionalized hafnium oxide nanoparticles (NBTXR3) have been developed as selective radioenhancers, which may represent a breakthrough approach for the local treatment of solid tumors. This is a unique approach where crystalline nanomaterials with high electron density when exposed to radiotherapy, can allow penetrate into the cell and make feasible the absorption/deposition of a high energy dose within the tumor cell. A phase I/II trial was implemented in patients with locally advanced STS.

2011 – CLINAM Abstract – Thermosensitive Magnetoliposomes for MRI-Guided Drug Delivery – Meyr et al.

Congress Abstracts, Miscellaneous

Congress: CLINAM, 23rd May 2011 – The development of new activatable drug nanocarriers, with multiple functionalities, presents a promising approach for cancer treatment. Improved drug delivery and controlled drug release at the tumor site may have considerable benefit by increasing treatment efficacy while reducing side effects and toxicity. Further, the possibility to monitor both nanocarrier accumulation and drug release via current clinical imaging techniques may be particularly relevant for an optimal treatment.

2011 – ECCO Abstract – NBTXR3 as promising cancer therapy – Magiorella et al.

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

We created and developed NBTXR3 nanoparticles with a crystalline hafnium oxide core which provide high electron density structure and inert behavior in biological media. NBTXR3 nanoparticles’ characteristics, size, charge and shape, allow for efficient interaction with biological entities, cell membrane binding and cellular uptake. The nanoparticles were shown to form clusters at the subcellular level in tumor models. Of most importance, we show NBTXR3 intratumor bioavailability with dispersion of nanoparticles in the three dimensions and persistence within the tumor structure, supporting the use of NBTXR3 as effective antitumor therapeutic agent.

2011 – AACR Abstract – NBTXR3 radioenhancement and anti-tumor effect in vitro – Magiorella et al.

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Local and systemic control of Soft Tissue Sarcoma (STS) remains a clinical challenge. Radiation therapy is part of the standard of care of STS. The narrowness of its therapeutic window represents the main concern for different clinical settings. Thus, local delivery of radiation doses is critical to ensure optimal benefit-risk ratio. NBTXR3, biocompatible hafnium oxide nanoparticles were designed as therapeutics to be activated by ionizing radiation to achieve tumor control by enhancement of local energy deposition.

2010 – GDR Photomed Abstract – Silica Nanoparticles for Photodynamic Therapy – Thienot et al.

Congress Abstracts, Miscellaneous

Photodynamic therapy in the elderly and heavily pretreated cancer patient populations may represent a promising therapeutical option in the management of malignant diseases provided that different approaches bring real improvement for its clinical application. Silica-based nanocarrier encapsulating photosensitizers, the protoporphyrin IX (Pp IX), have been designed to improve the tumor bioavailability, to reduce photosensitizer accumulation in the skin and to differentially deliver the nanocarriers to cell organelles.

2010 – CLINAM Abstract – Expected and Unexpected Side Effects of Nanodrugs – Levy et al.

Congress Abstracts, Miscellaneous

Nanotechnology offers revolutionary strategies to improve healthcare. Adequate nanomaterial characterization constitutes the basis to establish relevant programs of nanoparticle/biological systems cross talk evaluation. Also, the surrounding conditions significantly impact on the state of the nanoparticles in terms of their collective behavior: dispersion, aggregation, and stability in gas or liquid.

2010 – ESTRO Abstract – hafnium Oxide nanoparticles as anti cancer agent – Deutsch et al.

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Nanotechnology is the engineering of objects at the nanometer scale with novel properties. Nanotechnology is being applied to medicine leading to novel diagnostic or treatment applications. Nanoscale objects are about one hundred to ten thousand times smaller than human cells. They are similar in size to large biological molecules ("biomolecules") such as enzymes and receptors. As an example, hemoglobin, the molecule that carries oxygen in red blood cells, is approximately 5 nanometers in diameter. Nanoscale objects smaller than 100 nanometers can move out of blood vessels as they circulate through the body due to morphological features of the endothelium (fenestrae size). Those smaller than 7 nanometers can be cleared from the body by the kidney, as they circulate.

Congresses are a key element for Nanobiotix to publish scientific data and results. This section lists abstracts that have been published by Nanobiotix over the last decade.